WeVote

Bill

Bill

S 1602

An Act improving pediatric cancer research

194th Legislature (2025-2026) Introduced by Paul Feeney and 6 co-sponsors

Massachusetts bill to enhance pediatric cancer research; currently in Health Care Financing committee after favorable public health committee review in February-October 2025.

Accompanied a study order, see S2931
0
WeVote Research Nonpartisan
Bill Summary · S 1602

Legislative bill overview

S 1602 is a Massachusetts bill designed to enhance pediatric cancer research initiatives within the state. The bill has progressed through initial committee review and received a favorable report, currently moving through the Health Care Financing committee stage. The specific mechanisms for improvement—such as funding allocations, research partnerships, or institutional requirements—are not detailed in the available action history.

Why is this important

Pediatric cancer remains a leading cause of disease-related death in children, and research advancement depends on sustained funding and institutional support. Massachusetts, home to major medical research centers, plays a significant role in national cancer research efforts, making state-level support meaningful for both local patients and broader scientific progress.

Potential points of contention

  • Funding source and amount: The bill's fiscal impact and whether it requires new appropriations, tax adjustments, or reallocation of existing healthcare budgets remains unclear and could face budget committee scrutiny
  • Definition of "improvement": Without seeing the full text, it's unclear whether the bill mandates specific research priorities, institutional partnerships, or regulatory changes that some stakeholders might view as overreach
  • Implementation logistics: Questions may arise about which institutions qualify for support, how research directions are selected, and whether the bill balances competitive funding fairly across medical centers

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.